Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

mIF_Church

Our research aims to understand the origins of tumours and the mechanisms through which they evade immune surveillance. We focus particularly on colorectal and endometrial cancers — two of the most common and clinically challenging tumour types — to uncover how genetic mutations and immune interactions shape disease progression.

A central theme of our work is antigen presentation, which plays a crucial role in determining whether the immune system can recognise and eliminate tumour cells. We investigate how DNA mutations characteristic of these cancers influence the repertoire of tumour-associated antigens and how T cells respond to them. By integrating multi-layered genomic and immunological data, we seek to define the key features that enable tumours to grow, adapt, and escape immune detection.

To achieve this, we employ a wide range of state-of-the-art sequencing technologies, including WGS, RNAseq, spatial transcriptomics, and TCRseq. These approaches allow us to dissect tumour–immune dynamics at single-cell and spatial resolution, providing a comprehensive view of cancer–immune co-evolution.

Our studies combine correlative analyses of human tumours with cancer models that recapitulate the mutations found in human HLA genes and their consequences for immune recognition. We use functional systems that faithfully mimic disease development and immune escape, alongside analyses of patient samples obtained through collaborations with academic and industry partners.

Ultimately, our goal is to translate these insights into novel biomarkers and therapeutic strategies, with a particular emphasis on cancer interception and therapeutic vaccination. Through this integrated approach, we aim to contribute to the development of more effective and personalised immunotherapies that improve patient outcomes.

Collaborations

LynchVax group

TransPORTEC group

TransSCOT group 

Links

Genomics England

Our team

Selected publications